Concept explainers
To determine: The ways by which the potential to differentiate leukemic cells from healthy cells provides an opportunity to develop a therapy for CML treatment.
Introduction: In the case of CML (chronic myelogenous leukemia), leukemic cells can be distinguished from healthy body cells. This difference occurs due to the presence of functional BCR-ABL hybrid protein.
Explanation of Solution
One of the approaches that can be utilized to fight CML includes the use of tyrosine kinase inhibitor. This inhibitor binds to the ATP binding site of ABL kinase by inhibiting BCR-ABL phosphorylation and preventing the activation signaling pathways.
Moreover, real-time Q-RT-PCR (quantitative reverse transcription-polymerase chain reaction) allows an individual to monitor drug responses of cell populations in the patient. This approach is used to develop less toxic and effective treatments.
The potential to differentiate leukemic cells from normal cells allows an individual not to target therapy to specific cell populations but also to quantify responses to therapy. The leukemic cells produce an unusual hybrid protein known as BCR-ABL. Therefore, it may be possible to develop a therapy such as immunotherapy, based on the uniqueness of BCR-ABL protein.
Thus, the uniqueness of BCR-ABL protein may be used to develop immunotherapy for CML treatment.
Want to see more full solutions like this?
Chapter 24 Solutions
Concepts of Genetics (12th Edition)
- Explain why the gene for sickle cell anemia may be beneficial to humans at some point. Describe these conditions.arrow_forwardWhat are the causes of thrombophilia? Describe the laboratory tests that are used to confirm the molecular cause of the condition in a patient.arrow_forwardExplain why mutational resistance in Mycobacterium tuberculosis is of much importance in the treatment of tuberculosis.arrow_forward
- 1) A) List 15 drugs (monoclonal antibodies can be used) used clinically to treat cancer in humans. These targets must be signal transduction pathway components. B) For each drug, list the specific protein targeted. C) For each drug, describe the efficacy of treatment (i.e. what is the success rate in life extension) as well as appropriate cost of treatment whether it be per round or an average annual cost.arrow_forwardDescribe the mutational event that produces the MYC oncogene in Burkitt’s lymphoma. Why does the particular mechanism for generating oncogenic MYC result in a lymphoma rather than another type of cancer? Describe another mechanism for generating oncogenic MYC.arrow_forwardwhat is The genetic basis for chronic myelogenous leukemia ?arrow_forward
- Why is DNA testing used for a patient with sickle cell anemia?arrow_forwardDistinguish between What is known of CD105 (endoglin) as an hepatcellular carcinoma marker and it’s potential as a drug target. Discuss: - Is anything known about its biology? E.g does it have known ligands and normal functions? - if you were to target it would you just use it to get growth inhibiting compound into the new blood vessels or is CD105 required for neovascularization?arrow_forwardFlow cytometry analysis was performed on the blood of an individual known to have been recently exposed to both rhinovirus (RV) and Mycobacterium tuberculosis (M.tb; an intracellular bacterial pathogen). Although an effective T cell response against RV was detected, a T cell response against M.tb was absent. Subsequently, genetic testing was performed, and the individual was found to possess two mutations. Below, indicate the MOST LIKELY mutations. A. T-bet; IL-12 B. CD28: IL-2Ra C. RORyT: IL-17 D. CD3: CD4arrow_forward
- How do loss of function mutations associated with Artemis (protein) cause their resulting phenotypes? Explain how genetically modified HSCs can treat these phenotypes.arrow_forwardWhat is the role of genomics in generating anti-SEMA3A monoclonal antibodies as a potential therapeutic antibody against GBM progression? Explain in detailed manner.arrow_forwardBecause of oxygen and nutrient requirements, cells in a tissue must reside within 100 μm of a blood vessel. Based on this information, explain why many malignant tumors often possess gain-of-function mutations in one of the following genes: βFGF, TGF-α, and VEGF.arrow_forward
- Human Heredity: Principles and Issues (MindTap Co...BiologyISBN:9781305251052Author:Michael CummingsPublisher:Cengage Learning